Showing results (121-130 of 152) with videos related to
Sort By:
Pageof 16
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 10, 2019
Patient-Centered Standards for Medically Integrated Dispensing: ASCO/NCODA StandardsMelissa S Dillmon, Erin B Kennedy, Mary K Anderson, et al.Cancer Discovery|October 10, 2020
Precision Prevention and Cancer Interception: The New Challenges of Liquid BiopsyMaria Jose Serrano, Maria Carmen Garrido-Navas, Juan Jose Diaz Mochon, et al.The Oncologist|May 10, 2022
Larotrectinib Treatment for Patients With TRK Fusion-Positive Salivary Gland CancersXiuning Le, Christina Baik, Jessica Bauman, et al.Cancer Treatment Reviews|June 24, 2014
Novel therapeutic strategies for patients with NSCLC that do not respond to treatment with EGFR inhibitorsChristian Rolfo, Elisa Giovannetti, David S Hong, et al.Cancer Research Communications|August 5, 2025
Phase 2 Study of Zilovertamab Vedotin in Participants With Metastatic Solid TumorsFunda Meric-Bernstam, Martin Gutierrez, Enrique Sanz-Garcia, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 2, 2010
A multicenter, phase 2 study of vascular endothelial growth factor trap (Aflibercept) in platinum- and erlotinib-resistant adenocarcinoma of the lungNatasha B Leighl, Luis E Raez, Benjamin Besse, et al.Lancet Regional Health. Americas|December 1, 2025
Corrigendum to "Clinical and economic impact of the availability of innovative therapies for advanced lung cancer in men in Latin America: a population-based secondary data study"- the Lancet Regional Health-Americas 2025; Volume 49: 101172; DOI: 10.1016/j.lana.2025.101172Andrés F Cardona, Natalia Sánchez, Liliana Gutiérrez-Babativ, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 2006
Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancerMichael P Fanucchi, Frank V Fossella, Robert Belt, et al.Biochemical and Biophysical Research Communications|April 22, 2018
Frequencies and expression levels of programmed death ligand 1 (PD-L1) in circulating tumor RNA (ctRNA) in various cancer typesToshiyuki Ishiba, Andreas-Claudius Hoffmann, Joshua Usher, et al.Lancet Regional Health. Americas|July 21, 2025
Clinical and economic impact of the availability of innovative therapies for advanced lung cancer in men in Latin America: a population-based secondary data studyAndrés F Cardona, Natalia Sánchez, Liliana Gutiérrez-Babativa, et al.Pageof 16